Secondary hyperparathyroidism
diseaseOn this page
Also known as secondary hyperparathyroidism (disease)secondary hyperparathyroidism NOS
Summary
Secondary hyperparathyroidism (MONDO:0006964) is a disease and 126 clinical trials. Top therapeutic interventions include cinacalcet, paricalcitol, and etelcalcetide. A subtype of hyperparathyroidism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 126
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | secondary hyperparathyroidism |
| Mondo ID | MONDO:0006964 |
| EFO | EFO:1001173 |
| MeSH | D006962 |
| DOID | DOID:12466 |
| ICD-11 | 1442752937 |
| NCIT | C113335 |
| SNOMED CT | 91478007 |
| UMLS | C0020503 |
| MedGen | 9368 |
| MedDRA | 10020708 |
| Is cancer (heuristic) | no |
Also known as: secondary hyperparathyroidism · secondary hyperparathyroidism (disease) · secondary hyperparathyroidism NOS
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of hyperparathyroidism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › parathyroid gland disorder › hyperparathyroidism › secondary hyperparathyroidism
Related subtypes (3): primary hyperparathyroidism, hereditary hyperparathyroidism, tertiary hyperparathyroidism
Subtypes (2): secondary hyperparathyroidism of renal origin, non-renal secondary hyperparathyroidism
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
3 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Doxercalciferol | Approved (phase 4) |
| Etelcalcetide | Approved (phase 4) |
| Paricalcitol | Approved (phase 4) |
| Cinacalcet | Phase 3 (in late-stage trials) |
| Evocalcet | Phase 3 (in late-stage trials) |
| Maxacalcitol | Phase 3 (in late-stage trials) |
| Upacicalcet | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Calcitriol, Calcium Carbonate, Sevelamer Hydrochloride.
Clinical trials & evidence
Clinical trials
Clinical trials: 126.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 36 |
| PHASE4 | 32 |
| PHASE3 | 26 |
| PHASE2 | 19 |
| PHASE1 | 9 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00053547 | PHASE4 | COMPLETED | Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis |
| NCT00073710 | PHASE4 | COMPLETED | Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium |
| NCT00123461 | PHASE4 | COMPLETED | Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism |
| NCT00132431 | PHASE4 | COMPLETED | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism |
| NCT00135304 | PHASE4 | COMPLETED | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism |
| NCT00175149 | PHASE4 | TERMINATED | Active Vitamin D Effect on Left Ventricular Hypertrophy |
| NCT00257920 | PHASE4 | COMPLETED | A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease |
| NCT00288873 | PHASE4 | COMPLETED | Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity |
| NCT00307840 | PHASE4 | COMPLETED | Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism |
| NCT00379899 | PHASE4 | COMPLETED | ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis |
| NCT00418600 | PHASE4 | COMPLETED | A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis |
| NCT00431496 | PHASE4 | COMPLETED | A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) |
| NCT00446329 | PHASE4 | TERMINATED | Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis |
| NCT00454350 | PHASE4 | COMPLETED | A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis |
| NCT00463021 | PHASE4 | COMPLETED | A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection |
| NCT00537979 | PHASE4 | COMPLETED | Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis |
| NCT00664430 | PHASE4 | TERMINATED | Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects |
| NCT00803712 | PHASE4 | COMPLETED | 20070360 Incident Dialysis |
| NCT00823303 | PHASE4 | COMPLETED | Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) |
| NCT00891813 | PHASE4 | COMPLETED | Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose |
| NCT00958451 | PHASE4 | COMPLETED | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
| NCT00977080 | PHASE4 | COMPLETED | Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D |
| NCT01025128 | PHASE4 | COMPLETED | Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density |
| NCT01100723 | PHASE4 | COMPLETED | Trial to Optimize Mineral Outcomes in Dialysis Patients |
| NCT01101113 | PHASE4 | COMPLETED | Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level |
| NCT01115543 | PHASE4 | COMPLETED | Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism |
| NCT01178450 | PHASE4 | COMPLETED | Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation |
| NCT01447368 | PHASE4 | COMPLETED | Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients |
| NCT01725113 | PHASE4 | TERMINATED | Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol |
| NCT02338934 | PHASE4 | UNKNOWN | Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients |
| NCT03023748 | PHASE4 | UNKNOWN | Intravenous Paricalcitol in Chronic Hemodialysis Patients |
| NCT03182699 | PHASE4 | COMPLETED | Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients |
| NCT03633708 | PHASE3 | RECRUITING | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis |
| NCT03969329 | PHASE3 | RECRUITING | A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis |
| NCT00037635 | PHASE3 | COMPLETED | A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients |
| NCT00042653 | PHASE3 | COMPLETED | A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis |
| NCT00117052 | PHASE3 | COMPLETED | SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism |
| NCT00345839 | PHASE3 | COMPLETED | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events |
| NCT00352170 | PHASE3 | COMPLETED | Calcium and Vitamin D Malnutrition in Elderly Women |
| NCT01012414 | PHASE3 | TERMINATED | Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CINACALCET | 4 | 61 |
| PARICALCITOL | 4 | 22 |
| ETELCALCETIDE | 4 | 8 |
| CALCITRIOL | 4 | 7 |
| CALCIFEDIOL | 4 | 4 |
| ERGOCALCIFEROL | 4 | 4 |
| CHOLECALCIFEROL | 4 | 3 |
| ALFACALCIDOL | 4 | 2 |
| DOXERCALCIFEROL | 4 | 2 |
| CALCIUM | 4 | 1 |
| CALCIUM CARBONATE | 4 | 1 |
| SEVELAMER CARBONATE | 4 | 1 |
| SEVELAMER HYDROCHLORIDE | 4 | 1 |
| TERIPARATIDE | 4 | 1 |
| EVOCALCET | 3 | 5 |
| UPACICALCET | 3 | 5 |
| MAXACALCITOL | 3 | 3 |
| LUNACALCIPOL | 2 | 2 |
| ASP7991 | 2 | 1 |
| DP001 | 2 | 1 |
| CHEMBL50241 | 0 | 2 |
| CHEMBL443232 | 0 | 1 |
| CHEMBL5072826 | 0 | 1 |